Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense

Fabrice E. Graf, Philipp Ludin, Christian Arquint, Remo S. Schmidt, Nadia Schaub, Christina Kunz Renggli, Jane C. Munday, Jessica Krezdorn, Nicola Baker, David Horn, Oliver Balmer, Adalgisa Caccone, Harry P. de Koning, Pascal Mäser (Lead / Corresponding author)

Research output: Contribution to journalArticle

11 Citations (Scopus)
112 Downloads (Pure)

Abstract

Trypanosoma brucei rhodesiense is one of the causative agents of human sleeping sickness, a fatal disease that is transmitted by tsetse flies and restricted to Sub-Saharan Africa. Here we investigate two independent lines of T. b. rhodesiense that have been selected with the drugs melarsoprol and pentamidine over the course of 2 years, until they exhibited stable cross-resistance to an unprecedented degree. We apply comparative genomics and transcriptomics to identify the underlying mutations. Only few mutations have become fixed during selection. Three genes were affected by mutations in both lines: the aminopurine transporter AT1, the aquaporin AQP2, and the RNA-binding protein UBP1. The melarsoprol-selected line carried a large deletion including the adenosine transporter gene AT1, whereas the pentamidine-selected line carried a heterozygous point mutation in AT1, G430R, which rendered the transporter non-functional. Both resistant lines had lost AQP2, and both lines carried the same point mutation, R131L, in the RNA-binding motif of UBP1. The finding that concomitant deletion of the known resistance genes AT1 and AQP2 in T. b. brucei failed to phenocopy the high levels of resistance of the T. b. rhodesiense mutants indicated a possible role of UBP1 in melarsoprol–pentamidine cross-resistance. However, homozygous in situ expression of UBP1-Leu131 in T. b. brucei did not affect the sensitivity to melarsoprol or pentamidine.

Original languageEnglish
Pages (from-to)3387-3400
Number of pages14
JournalCellular and Molecular Life Sciences
Volume73
Issue number17
Early online date14 Mar 2016
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Melarsoprol
Trypanosoma brucei rhodesiense
Pentamidine
Genomics
Drug Resistance
Point Mutation
Mutation
Genes
Tsetse Flies
Aquaporins
RNA-Binding Proteins
Africa South of the Sahara
Pharmaceutical Preparations

Keywords

  • African trypanosomes
  • Aquaporin
  • Melarsoprol
  • Pentamidine
  • Purine permease
  • RNA-binding protein

Cite this

Graf, F. E., Ludin, P., Arquint, C., Schmidt, R. S., Schaub, N., Kunz Renggli, C., ... Mäser, P. (2016). Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense. Cellular and Molecular Life Sciences, 73(17), 3387-3400. https://doi.org/10.1007/s00018-016-2173-6
Graf, Fabrice E. ; Ludin, Philipp ; Arquint, Christian ; Schmidt, Remo S. ; Schaub, Nadia ; Kunz Renggli, Christina ; Munday, Jane C. ; Krezdorn, Jessica ; Baker, Nicola ; Horn, David ; Balmer, Oliver ; Caccone, Adalgisa ; de Koning, Harry P. ; Mäser, Pascal. / Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense. In: Cellular and Molecular Life Sciences. 2016 ; Vol. 73, No. 17. pp. 3387-3400.
@article{deeee6a8cf5e41c6bd00a934a0aa47c1,
title = "Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense",
abstract = "Trypanosoma brucei rhodesiense is one of the causative agents of human sleeping sickness, a fatal disease that is transmitted by tsetse flies and restricted to Sub-Saharan Africa. Here we investigate two independent lines of T. b. rhodesiense that have been selected with the drugs melarsoprol and pentamidine over the course of 2 years, until they exhibited stable cross-resistance to an unprecedented degree. We apply comparative genomics and transcriptomics to identify the underlying mutations. Only few mutations have become fixed during selection. Three genes were affected by mutations in both lines: the aminopurine transporter AT1, the aquaporin AQP2, and the RNA-binding protein UBP1. The melarsoprol-selected line carried a large deletion including the adenosine transporter gene AT1, whereas the pentamidine-selected line carried a heterozygous point mutation in AT1, G430R, which rendered the transporter non-functional. Both resistant lines had lost AQP2, and both lines carried the same point mutation, R131L, in the RNA-binding motif of UBP1. The finding that concomitant deletion of the known resistance genes AT1 and AQP2 in T. b. brucei failed to phenocopy the high levels of resistance of the T. b. rhodesiense mutants indicated a possible role of UBP1 in melarsoprol–pentamidine cross-resistance. However, homozygous in situ expression of UBP1-Leu131 in T. b. brucei did not affect the sensitivity to melarsoprol or pentamidine.",
keywords = "African trypanosomes, Aquaporin, Melarsoprol, Pentamidine, Purine permease, RNA-binding protein",
author = "Graf, {Fabrice E.} and Philipp Ludin and Christian Arquint and Schmidt, {Remo S.} and Nadia Schaub and {Kunz Renggli}, Christina and Munday, {Jane C.} and Jessica Krezdorn and Nicola Baker and David Horn and Oliver Balmer and Adalgisa Caccone and {de Koning}, {Harry P.} and Pascal M{\"a}ser",
year = "2016",
month = "9",
doi = "10.1007/s00018-016-2173-6",
language = "English",
volume = "73",
pages = "3387--3400",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Springer Verlag",
number = "17",

}

Graf, FE, Ludin, P, Arquint, C, Schmidt, RS, Schaub, N, Kunz Renggli, C, Munday, JC, Krezdorn, J, Baker, N, Horn, D, Balmer, O, Caccone, A, de Koning, HP & Mäser, P 2016, 'Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense', Cellular and Molecular Life Sciences, vol. 73, no. 17, pp. 3387-3400. https://doi.org/10.1007/s00018-016-2173-6

Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense. / Graf, Fabrice E.; Ludin, Philipp; Arquint, Christian; Schmidt, Remo S.; Schaub, Nadia; Kunz Renggli, Christina; Munday, Jane C.; Krezdorn, Jessica; Baker, Nicola; Horn, David; Balmer, Oliver; Caccone, Adalgisa; de Koning, Harry P.; Mäser, Pascal (Lead / Corresponding author).

In: Cellular and Molecular Life Sciences, Vol. 73, No. 17, 09.2016, p. 3387-3400.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense

AU - Graf, Fabrice E.

AU - Ludin, Philipp

AU - Arquint, Christian

AU - Schmidt, Remo S.

AU - Schaub, Nadia

AU - Kunz Renggli, Christina

AU - Munday, Jane C.

AU - Krezdorn, Jessica

AU - Baker, Nicola

AU - Horn, David

AU - Balmer, Oliver

AU - Caccone, Adalgisa

AU - de Koning, Harry P.

AU - Mäser, Pascal

PY - 2016/9

Y1 - 2016/9

N2 - Trypanosoma brucei rhodesiense is one of the causative agents of human sleeping sickness, a fatal disease that is transmitted by tsetse flies and restricted to Sub-Saharan Africa. Here we investigate two independent lines of T. b. rhodesiense that have been selected with the drugs melarsoprol and pentamidine over the course of 2 years, until they exhibited stable cross-resistance to an unprecedented degree. We apply comparative genomics and transcriptomics to identify the underlying mutations. Only few mutations have become fixed during selection. Three genes were affected by mutations in both lines: the aminopurine transporter AT1, the aquaporin AQP2, and the RNA-binding protein UBP1. The melarsoprol-selected line carried a large deletion including the adenosine transporter gene AT1, whereas the pentamidine-selected line carried a heterozygous point mutation in AT1, G430R, which rendered the transporter non-functional. Both resistant lines had lost AQP2, and both lines carried the same point mutation, R131L, in the RNA-binding motif of UBP1. The finding that concomitant deletion of the known resistance genes AT1 and AQP2 in T. b. brucei failed to phenocopy the high levels of resistance of the T. b. rhodesiense mutants indicated a possible role of UBP1 in melarsoprol–pentamidine cross-resistance. However, homozygous in situ expression of UBP1-Leu131 in T. b. brucei did not affect the sensitivity to melarsoprol or pentamidine.

AB - Trypanosoma brucei rhodesiense is one of the causative agents of human sleeping sickness, a fatal disease that is transmitted by tsetse flies and restricted to Sub-Saharan Africa. Here we investigate two independent lines of T. b. rhodesiense that have been selected with the drugs melarsoprol and pentamidine over the course of 2 years, until they exhibited stable cross-resistance to an unprecedented degree. We apply comparative genomics and transcriptomics to identify the underlying mutations. Only few mutations have become fixed during selection. Three genes were affected by mutations in both lines: the aminopurine transporter AT1, the aquaporin AQP2, and the RNA-binding protein UBP1. The melarsoprol-selected line carried a large deletion including the adenosine transporter gene AT1, whereas the pentamidine-selected line carried a heterozygous point mutation in AT1, G430R, which rendered the transporter non-functional. Both resistant lines had lost AQP2, and both lines carried the same point mutation, R131L, in the RNA-binding motif of UBP1. The finding that concomitant deletion of the known resistance genes AT1 and AQP2 in T. b. brucei failed to phenocopy the high levels of resistance of the T. b. rhodesiense mutants indicated a possible role of UBP1 in melarsoprol–pentamidine cross-resistance. However, homozygous in situ expression of UBP1-Leu131 in T. b. brucei did not affect the sensitivity to melarsoprol or pentamidine.

KW - African trypanosomes

KW - Aquaporin

KW - Melarsoprol

KW - Pentamidine

KW - Purine permease

KW - RNA-binding protein

UR - http://www.scopus.com/inward/record.url?scp=84961127622&partnerID=8YFLogxK

U2 - 10.1007/s00018-016-2173-6

DO - 10.1007/s00018-016-2173-6

M3 - Article

C2 - 26973180

AN - SCOPUS:84961127622

VL - 73

SP - 3387

EP - 3400

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 17

ER -

Graf FE, Ludin P, Arquint C, Schmidt RS, Schaub N, Kunz Renggli C et al. Comparative genomics of drug resistance in Trypanosoma brucei rhodesiense. Cellular and Molecular Life Sciences. 2016 Sep;73(17):3387-3400. https://doi.org/10.1007/s00018-016-2173-6